Also known as: CStone
CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on oncology, immunology, inflammation, and related disease areas. The company states it was established in 2015 and has launched multiple innovative drugs with additional candidates in development. It describes itself as addressing unmet medical needs in China and globally.
LigaChem Biosciences is expanding R&D investment in its ADC pipeline despite widening losses, with major clinical milestones expected this year. Concurrently, Lonza has enhanced its advanced synthesis capabilities for ADC development, including dual-payload technology and expanded Netherlands facility infrastructure.
CStone Pharmaceuticals has received FDA clearance for its IND application to initiate a Phase II trial of CS2009, a trispecific antibody targeting PD-1, VEGFA, and CTLA-4, in patients with advanced solid tumors across nine cancer indications.
CStone Pharmaceuticals received FDA IND clearance to initiate a Phase II trial of CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced solid tumors across nine cancer indications.
CStone Pharmaceuticals received FDA IND clearance to begin a Phase II trial of CS2009, a trispecific antibody targeting PD-1, VEGF, and CTLA-4, in advanced solid tumors across nine cancer indications.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06741644 |
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors |
RECRUITING | PHASE1/PHASE2 |
| NCT05700448 |
Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma |
NOT_YET_RECRUITING | PHASE3 |
| NCT05381753 |
Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World |
COMPLETED | |
| NCT05297890 |
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05279300 |
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas |
RECRUITING | PHASE1 |
| NCT04472858 |
A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors |
UNKNOWN | PHASE1 |
| NCT04421352 |
Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients |
COMPLETED | PHASE1 |
| NCT04338724 |
A Phase I Study of CS1002 in Subjects With Advanced Solid Tumors |
COMPLETED | PHASE1 |
| NCT04254939 |
A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor |
COMPLETED | PHASE1/PHASE2 |
| NCT04233060 |
A Study of CS3005 in Advanced Solid Tumors |
COMPLETED | PHASE1 |
